[go: up one dir, main page]

WO2008133137A1 - 遺伝子治療のためのベクター - Google Patents

遺伝子治療のためのベクター Download PDF

Info

Publication number
WO2008133137A1
WO2008133137A1 PCT/JP2008/057414 JP2008057414W WO2008133137A1 WO 2008133137 A1 WO2008133137 A1 WO 2008133137A1 JP 2008057414 W JP2008057414 W JP 2008057414W WO 2008133137 A1 WO2008133137 A1 WO 2008133137A1
Authority
WO
WIPO (PCT)
Prior art keywords
transcription
unit
vector
retroviral vector
manner
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/057414
Other languages
English (en)
French (fr)
Inventor
Hideto Chono
Kazuya Matsumoto
Hajime Matsumura
Junichi Mineno
Ikunoshin Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Priority to CN200880012249.7A priority Critical patent/CN101663397B/zh
Priority to JP2009511821A priority patent/JP5484897B2/ja
Priority to KR1020097021664A priority patent/KR101252065B1/ko
Priority to HK10108182.9A priority patent/HK1141831B/xx
Priority to US12/596,744 priority patent/US20100137415A1/en
Priority to EP08740493A priority patent/EP2138580B1/en
Publication of WO2008133137A1 publication Critical patent/WO2008133137A1/ja
Anticipated expiration legal-status Critical
Priority to US14/169,361 priority patent/US20140170709A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

　本発明は、転写調節配列と、前記配列により発現の制御が可能な形態に配置された一本鎖ＲＮＡ特異的なエンドリボヌクレア－ゼ活性を有するポリペプチドをコードする遺伝子からなる転写ユニットを含有するレトロウイルスベクターであって、前記ユニットからのｍＲＮＡの転写方向がレトロウイルスベクターのＲＮＡゲノムの転写方向に対して逆向きとなるように前記ユニットが配置されていることを特徴とするレトロウイルスベクターを提供する。前記の構成のベクターを使用することにより、高い遺伝子導入効率を示すウイルス上清を調製することができる。本発明のレトロウイルスベクターは、がんやウイルス感染症の治療、予防に有用である。
PCT/JP2008/057414 2007-04-20 2008-04-16 遺伝子治療のためのベクター Ceased WO2008133137A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN200880012249.7A CN101663397B (zh) 2007-04-20 2008-04-16 用于基因治疗的载体
JP2009511821A JP5484897B2 (ja) 2007-04-20 2008-04-16 遺伝子治療のためのベクター
KR1020097021664A KR101252065B1 (ko) 2007-04-20 2008-04-16 유전자 치료를 위한 벡터
HK10108182.9A HK1141831B (en) 2007-04-20 2008-04-16 Vector for gene therapy
US12/596,744 US20100137415A1 (en) 2007-04-20 2008-04-16 Vector for gene therapy
EP08740493A EP2138580B1 (en) 2007-04-20 2008-04-16 Vector for gene therapy
US14/169,361 US20140170709A1 (en) 2007-04-20 2014-01-31 Vector for gene therapy

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2007-112178 2007-04-20
JP2007112178 2007-04-20
JP2007-138889 2007-05-25
JP2007138889 2007-05-25
JP2007-268310 2007-10-15
JP2007268310 2007-10-15
JP2008025248 2008-02-05
JP2008-025248 2008-02-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/596,744 A-371-Of-International US20100137415A1 (en) 2007-04-20 2008-04-16 Vector for gene therapy
US14/169,361 Division US20140170709A1 (en) 2007-04-20 2014-01-31 Vector for gene therapy

Publications (1)

Publication Number Publication Date
WO2008133137A1 true WO2008133137A1 (ja) 2008-11-06

Family

ID=39925593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057414 Ceased WO2008133137A1 (ja) 2007-04-20 2008-04-16 遺伝子治療のためのベクター

Country Status (7)

Country Link
US (2) US20100137415A1 (ja)
EP (1) EP2138580B1 (ja)
JP (1) JP5484897B2 (ja)
KR (1) KR101252065B1 (ja)
CN (1) CN101663397B (ja)
TW (1) TWI411682B (ja)
WO (1) WO2008133137A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046727A1 (ja) 2010-10-05 2012-04-12 タカラバイオ株式会社 ウイルスベクターの製造方法
WO2012118092A1 (ja) * 2011-03-01 2012-09-07 タカラバイオ株式会社 融合タンパク質
WO2013141133A1 (ja) 2012-03-22 2013-09-26 タカラバイオ株式会社 ウイルスベクターの製造方法
WO2014092090A1 (ja) * 2012-12-11 2014-06-19 タカラバイオ株式会社 ウイルスベクター産生細胞及びベクターの製造方法
JP2020078326A (ja) * 2009-03-02 2020-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1921136B1 (en) 2005-08-16 2012-12-12 Takara Bio, Inc. Nucleic acid for treatment or prevention of immunodeficiency virus infection
WO2019083976A1 (en) 2017-10-23 2019-05-02 Yuntao Wu REV-DEPENDENT LENTIVIRAL VACCINE PARTICLES FOR REDUCING VIRAL REBOUND AND IN VIVO VIRAL TANKS
FR3158515A1 (fr) * 2024-01-23 2025-07-25 Asfalia Biologics Production de vecteurs toxiques
FR3158516A1 (fr) * 2024-01-23 2025-07-25 Asfalia Biologics Production de vecteurs toxiques
FR3158514A1 (fr) * 2024-01-23 2025-07-25 Asfalia Biologics Système de régulation de l’expression d’un transgène d’intérêt

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007943A1 (en) 1990-10-31 1992-05-14 Somatix Therapy Corporation Retroviral vectors useful for gene therapy
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
WO1995026200A1 (en) 1994-03-25 1995-10-05 Indiana University Foundation Enhanced virus-mediated dna transfer
US5554528A (en) 1987-08-21 1996-09-10 Board Of Revents Of University Of Colorado Compositions and methods for inhibition of HIV production
WO1997018318A1 (fr) 1995-11-13 1997-05-22 Takara Shuzo Co., Ltd. Procede d'introduction de genes dans des cellules cibles au moyen de retrovirus
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO2004113498A2 (en) 2003-06-13 2004-12-29 University Of Medicine And Dentistry Of New Jersey Rna interferases and methods of use thereof
JP2005510455A (ja) * 2001-05-04 2005-04-21 テクノロジー・インテグラル・エルティーディー 抗ウイルス剤
WO2006123537A1 (ja) 2005-05-16 2006-11-23 Takara Bio Inc. 新規なエンドリボヌクレア－ゼ
WO2007010740A1 (ja) 2005-07-21 2007-01-25 Takara Bio Inc. 新規なエンドリボヌクレアーゼ
WO2007013264A1 (ja) 2005-07-26 2007-02-01 Takara Bio Inc. 新規なエンドリボヌクレアーゼ
WO2007013265A1 (ja) 2005-07-26 2007-02-01 Takara Bio Inc. 新規なエンドリボヌクレアーゼ
WO2007020873A1 (ja) 2005-08-16 2007-02-22 Takara Bio Inc. 免疫不全ウイルス感染症の治療または予防のための核酸

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554528A (en) 1987-08-21 1996-09-10 Board Of Revents Of University Of Colorado Compositions and methods for inhibition of HIV production
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1992007943A1 (en) 1990-10-31 1992-05-14 Somatix Therapy Corporation Retroviral vectors useful for gene therapy
WO1995026200A1 (en) 1994-03-25 1995-10-05 Indiana University Foundation Enhanced virus-mediated dna transfer
WO1997018318A1 (fr) 1995-11-13 1997-05-22 Takara Shuzo Co., Ltd. Procede d'introduction de genes dans des cellules cibles au moyen de retrovirus
JP2005510455A (ja) * 2001-05-04 2005-04-21 テクノロジー・インテグラル・エルティーディー 抗ウイルス剤
WO2004113498A2 (en) 2003-06-13 2004-12-29 University Of Medicine And Dentistry Of New Jersey Rna interferases and methods of use thereof
JP2007503218A (ja) * 2003-06-13 2007-02-22 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー Ｒｎａインターフェラーゼおよびその使用方法
WO2006123537A1 (ja) 2005-05-16 2006-11-23 Takara Bio Inc. 新規なエンドリボヌクレア－ゼ
WO2007010740A1 (ja) 2005-07-21 2007-01-25 Takara Bio Inc. 新規なエンドリボヌクレアーゼ
WO2007013264A1 (ja) 2005-07-26 2007-02-01 Takara Bio Inc. 新規なエンドリボヌクレアーゼ
WO2007013265A1 (ja) 2005-07-26 2007-02-01 Takara Bio Inc. 新規なエンドリボヌクレアーゼ
WO2007020873A1 (ja) 2005-08-16 2007-02-22 Takara Bio Inc. 免疫不全ウイルス感染症の治療または予防のための核酸

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
GENE THERAPY, vol. 11, 2004, pages 94 - 99
HUM. GENE THERAPY, vol. 10, 1999, pages 103 - 112
HUM. GENE THERAPY, vol. 2, 1991, pages 53 - 61
HUMAN GENE THERAPY, vol. 11, 2000, pages 1863 - 1874
HUMAN GENE THERAPY, vol. 9, 1998, pages 2243 - 2251
ISHIKAWA H. ET AL.: "Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 287, no. 4, 2001, pages 1034 - 1040, XP002965091 *
J. BIOL. CHEM., vol. 279, 2004, pages 20678 - 20684
J. VIROL., vol. 66, 1992, pages 7176 - 7182
J. VIROL., vol. 71, 1997, pages 4218 - 4225
MOLECULAR CELL, vol. 12, 2003, pages 913 - 920
NATURE MEDICINE, vol. 2, 1996, pages 876 - 882
NUCLEIC ACIDS RESEARCH, vol. 18, 1990, pages 3587 - 3596
PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 6460 - 6464
PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 365 - 369
RAGHEB J.A. ET AL.: "Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminse, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant", REV. HUM. GENE THER., vol. 10, no. 1, 1999, pages 103 - 112, XP000914890 *
See also references of EP2138580A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020078326A (ja) * 2009-03-02 2020-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
US11618888B2 (en) 2009-03-02 2023-04-04 The Regents Of The University Of California Tumor-selective E1A and E1B mutants
US12195766B2 (en) 2009-03-02 2025-01-14 The Regents Of The University Of California Tumor-selective E1a and E1b mutants
WO2012046727A1 (ja) 2010-10-05 2012-04-12 タカラバイオ株式会社 ウイルスベクターの製造方法
US9102943B2 (en) 2010-10-05 2015-08-11 Takara Bio Inc. Method for producing virus vector
WO2012118092A1 (ja) * 2011-03-01 2012-09-07 タカラバイオ株式会社 融合タンパク質
WO2013141133A1 (ja) 2012-03-22 2013-09-26 タカラバイオ株式会社 ウイルスベクターの製造方法
US9399780B2 (en) 2012-03-22 2016-07-26 Takara Bio Inc. Method for producing viral vector
WO2014092090A1 (ja) * 2012-12-11 2014-06-19 タカラバイオ株式会社 ウイルスベクター産生細胞及びベクターの製造方法

Also Published As

Publication number Publication date
JPWO2008133137A1 (ja) 2010-07-22
HK1141831A1 (en) 2010-11-19
TWI411682B (zh) 2013-10-11
KR101252065B1 (ko) 2013-04-12
CN101663397A (zh) 2010-03-03
EP2138580A1 (en) 2009-12-30
EP2138580A4 (en) 2010-12-29
EP2138580B1 (en) 2013-03-20
US20100137415A1 (en) 2010-06-03
KR20100015650A (ko) 2010-02-12
CN101663397B (zh) 2015-04-22
US20140170709A1 (en) 2014-06-19
TW200902715A (en) 2009-01-16
JP5484897B2 (ja) 2014-05-07

Similar Documents

Publication Publication Date Title
WO2008133137A1 (ja) 遺伝子治療のためのベクター
EP3586868A3 (en) Liver-specific nucleic acid regulatory elements and methods and use thereof
WO2007149852A3 (en) Modified factor viii and factor ix genes and vectors for gene therapy
WO2007130604A3 (en) Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
WO2007112097A3 (en) Novel signature self renewal gene expression programs
WO2005049846A3 (en) Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
UA89957C2 (ru) Химерные аденовирусы для применения для лечения злокачественного новообразования
WO2008104978A3 (en) Novel sirna structures
WO2008156702A3 (en) Bacteria mediated gene silencing
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2008060510A3 (en) Zinc finger nuclease for targeting the human glucocorticoid receptor locus
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2008132234A3 (en) Rna antagonist compounds for the modulation of beta-catenin
KR100469936B1 (ko) 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
WO2010011343A3 (en) Methods for treating viral disorders
WO2010151674A3 (en) Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
EP2527445A3 (en) Treatment and prevention of influenza
WO2009101149A3 (en) Anti-tumour effective paramyxovirus
WO2009099877A3 (en) Closterovirus vectors and methods
WO2006078284A3 (en) Methods and compositions related to antiviral therapy using algae and cyanobacteria
PH12022550282A1 (en) Viral particles for use in treating synucleinopathies such as parkinson`s diseases by gene therapy
WO2005123141A3 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
WO2008051523A3 (en) Carbazole derivatives useful as medicaments in cancer therapy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880012249.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740493

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009511821

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20097021664

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008740493

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12596744

Country of ref document: US

Ref document number: 6702/DELNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE